LURAP1L Inhibitors
LURAP1L inhibitors are a class of chemical compounds that specifically target the LURAP1L (Leucine-Rich Adaptor Protein 1-Like) protein. LURAP1L is known to function as a regulatory adaptor protein involved in the control of cell motility and cytoskeletal dynamics. It interacts with other proteins, including components of the WAVE regulatory complex, which is important for actin polymerization and the reorganization of the actin cytoskeleton. By inhibiting LURAP1L, these compounds would interfere with the protein's ability to regulate actin-based processes, potentially disrupting cellular functions such as migration, adhesion, and shape changes that are essential for various physiological processes.
LURAP1L inhibitors are designed as small molecules or peptides that selectively bind to functional domains of the protein, such as its leucine-rich repeats or regions responsible for protein-protein interactions. These inhibitors would act by preventing LURAP1L from forming complexes with its binding partners, thus impairing its role in cytoskeletal regulation. The identification and development of LURAP1L inhibitors would involve methods such as high-throughput screening of compound libraries to find potential inhibitors, followed by structure-activity relationship (SAR) studies to refine their specificity. Structural studies of LURAP1L using techniques like X-ray crystallography or molecular docking could provide insight into how inhibitors bind to the protein and block its function. Research into LURAP1L inhibitors could deepen our understanding of how cytoskeletal dynamics are controlled at the molecular level, offering insights into the mechanisms of cell movement and structural organization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Prevents NF-kappaB activation by inhibiting IκBα phosphorylation and blocking its degradation. LURAP1L's function could be modulated if it relies on downstream NF-kappaB activation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can prevent IκB degradation, thus inhibiting NF-kappaB activation. LURAP1L might be influenced by changes in proteasomal degradation dynamics. | ||||||
QNZ | 545380-34-5 | sc-200675 | 1 mg | $117.00 | 12 | |
Inhibits NF-kappaB activation by suppressing TNF-α induced NF-kappaB transcription. The suppression could indirectly modulate the function or activity of LURAP1L in the signaling cascade. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
Specifically inhibits IKK, blocking IκBα phosphorylation and thus NF-kappaB activation. LURAP1L might see altered interactions or activity if IKK-mediated signals are suppressed. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
Selectively inhibits IKK, preventing IκBα phosphorylation and NF-kappaB activation. This may affect LURAP1L if it functions downstream or parallel to IKK in the pathway. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
Inhibits NF-kappaB transcriptional activity directly, without affecting IκBα degradation or p65 translocation. This might influence LURAP1L's role in the broader NF-kappaB activation processes. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
Blocks NF-kappaB activation by covalently modifying reduced cysteine 62 of p50. As LURAP1L is involved in this pathway, it could experience altered activity or interactions. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $110.00 $337.00 | 8 | |
Inhibits IKK activity, preventing NF-kappaB activation. With LURAP1L's involvement in this signaling, its function might be indirectly modulated. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
Inhibits IKKβ, preventing IκBα phosphorylation and subsequent NF-kappaB activation. This may influence the broader context in which LURAP1L operates within the signaling pathway. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
IKKβ inhibitor, blocking the phosphorylation of IκBα and preventing NF-kappaB activation. LURAP1L's interactions or activity in this pathway might be affected. | ||||||